Acer Therapeutics Inc (ACER)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

ONE GATEWAY CENTER (300 WASHINGTON ST.) NEWTON, MA 02458

Acer Therapeutics Inc. operates as a pharmaceutical company. The Company develops therapies for the treatment of ultra-rare diseases with critical unmet medical need. Acer Therapeutics offers therapies for vascular ehlers-danlos syndrome and maple syrup urine diseases. Acer Therapeutics serves patients in the United States.

Data as of 2020-11-22
Market Cap33.538 Million Shares Outstanding12.285 Million Avg 30-day Volume56.292 Thousand
P/E Ratio-1.3 Dividend Yield EPS-2.07
Price/Sales Price cash flow ratio Price free cash flow ratio-2.0
Book Value0.86 Price to Tangible Book12.25 Alpha-0.01
Short Interest Ratio % Short Interest to Float R-squared0.069619
BETA1.80058 52-week High/Low7.25 / 1.08 Stddev0.287573
View SEC Filings from ACER instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 28 35 -20.0% 7 (0.46%) 8 (0.52%) -12.5%
13F shares: 1.92 Million 2.002 Million -4.09% 1.415 Million 1.263 Million 12.04%
% Ownership 16.1198 16.9567 -4.94% 11.8813 10.6982 11.06%
New Positions: 3 8 -62.5% 1 4 -75.0%
Increased Positions 4 5 -20.0% 2
Closed Positions 10 11 -9.09% 2
Reduced Positions 12 17 -29.41% 1 3 -66.67%
Total Calls 0 0
Total Puts 0 0
PUT/CALL Ratio
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ACER (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ACER BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SCHELLING CHRIS PRESIDENT & CEO

  • Officer
  • Director
  • 10% Owner
1,892,857 2020-07-24 1

ASELAGE STEVE

  • Director
63,905 2020-07-24 2

DUNN JOHN MICHAEL

  • Director
27,380 2020-07-24 2

JOSEPH DONALD CHIEF LEGAL OFFICER AND SECY

  • Officer
14,285 2020-07-24 1

ANDREWS WILLIAM T. CHIEF MEDICAL OFFICER

  • Officer
5,858 2020-03-02 1

AMELLO JASON

  • Director
0 2020-01-02 1

GRIFFIN MICHELLE RENEE

  • Director
0 2020-01-02 1

PALMIN HARRY S CHIEF OPP. AND FINANCIAL OFFR

  • Officer
0 2019-09-18 0

SEIBT MATTHEW CHIEF COMMERCIAL OFFICER

  • Officer
0 2019-09-18 0

KLOPP JOHN MICHAEL CHIEF TECHNOLOGY OFFICER

  • Officer
0 2019-09-18 0

JUTT-EGHBALI SALMA CHIEF COMMERCIAL OFFICER

  • Officer
0 2018-12-04 0

TVM LIFE SCIENCE VENTURES VII L.P.

BIRNER HUBERT

MARENGERE LUC

FISCHER STEFAN

SCHUHSLER HELMUT

BEEBY RESHENTHA

LEATT GARY

  • Director
  • 10% Owner
1,697,709 2018-08-01 0

TVM LIFE SCIENCE VENTURES VI GMBH & CO KG

TVM LIFE SCIENCE VENTURES VI LP

TVM LIFE SCIENCE VENTURES VII L.P.

BIRNER HUBERT

MARENGERE LUC

FISCHER STEFAN

SCHUHSLER HELMUT

WANLESS MARK

LEATT GARY

  • Director
  • 10% Owner
2,397,309 2017-12-12 0

STEINER ROBERT D CHIEF MEDICAL OFFICER

0 2017-09-19 0

BARABE TIMOTHY C

  • Director
12,910 2016-11-18 0

MADERIS GAIL J

  • Director
25,884 2016-09-30 0

RICHMAN MICHAEL

  • Director
25,884 2016-09-30 0

SEAMAN SCOTT B

  • Director
159,665 2016-09-30 0

WARMA NEIL K PRESIDENT, CEO AND ACTING CFO

  • Officer
  • Director
0 2016-05-16 0

RILL DONNA R CHIEF DEVELOPMENT OFFICER

  • Officer
0 2016-05-16 0

HEALEY DON CHIEF SCIENTIFIC OFFICER

  • Officer
0 2016-05-16 0

RADHAKRISHNAN KARTHIK CHIEF FINANCIAL OFFICER

  • Officer
124,659 2015-04-08 0

HARTUNG HANS-PETER

  • Director
0 2015-03-30 0

JORDEN DAVID EMERSON

  • Director
293,456 2013-09-24 0

THOMPSON JAYE SVP CLINICAL DEV & REG AFFAIRS

  • Officer
0 2012-09-12 0

HUNG DAVID

  • Director
0 2011-04-05 0

MCWILLIAMS DAVID

  • Director
0 2009-08-26 0

SHEEDY CHARLES E

  • 10% Owner
752,354 2009-04-14 0

WILLIAMS JIMMY CALVIN CHIEF OPERATING OFFICER

  • Officer
0 2009-02-06 0

HOHLFELD LYNNE CFO

  • Officer
0 2009-01-16 0

ROTH MICHAEL

STARK BRIAN JAY

  • 10% Owner
No longer subject to file 2008-09-19 0

MARXE AUSTIN W & GREENHOUSE DAVID M

  • 10% Owner
746,848 2008-09-02 0

BAILEY GREGORY

  • Director
0 2008-06-26 0

RANDALL LORIN

  • Director
0 2008-06-26 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments